INNOVATE Corp. (VATE)
| Market Cap | 148.56M +75.8% |
| Revenue (ttm) | 1.34B +25.4% |
| Net Income | -56.40M |
| EPS | -4.25 |
| Shares Out | 13.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,589 |
| Open | 10.63 |
| Previous Close | 10.66 |
| Day's Range | 10.41 - 11.26 |
| 52-Week Range | 3.75 - 13.46 |
| Beta | 2.29 |
| Analysts | Strong Buy |
| Price Target | 50.00 (+359.14%) |
| Earnings Date | May 14, 2026 |
About VATE
INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The company operates through the Infrastructure, Life Sciences, and Spectrum segments. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; 3-D building information modeling and detailin... [Read more]
Financial Performance
In 2025, INNOVATE's revenue was $1.25 billion, an increase of 12.55% compared to the previous year's $1.11 billion. Losses were -$64.00 million, 78.8% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for VATE stock is "Strong Buy" and the 12-month stock price target is $50.0.
News
INNOVATE Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 33% year-over-year to $364.8M, driven by infrastructure growth, while net loss narrowed to $17.2M. Infrastructure backlog and cash position improved, but Life Sciences and Spectrum faced revenue declines.
INNOVATE Corp. Announces First Quarter 2026 Results
- Infrastructure: Strong first quarter results with revenue of $357.9 million - Life Sciences: MediBeacon receives the CE mark for the Transdermal GFR Monitor and Reusable Sensor - Spectrum: More tha...
INNOVATE Corp. to Report First Quarter 2026 Results on May 14th
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2026 on Thursday...
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated s...
MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in...
INNOVATE Earnings Call Transcript: Q4 2025
Fourth quarter revenue surged 61.7% year-over-year, driven by infrastructure, while net loss narrowed. Life sciences and spectrum segments faced headwinds, but regulatory wins and backlog growth position the company for 2026 expansion.
INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to de...
INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2...
Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
INNOVATE Corp.’s DBM Global to pay $1.30 per share dividend
INNOVATE Corp. (VATE) announced that DBM Global, an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5M, or $1.30 per share, on February 24, 2026 to DBMG’s…
INNOVATE announces MediBeacon received approval for TGFRTM System
INNOVATE announced that MediBeacon, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration, FDA, for the next generation MediBeacon TGFRTM Sys...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
INNOVATE Earnings Call Transcript: Q3 2025
Q3 2025 revenue rose 43% year-over-year to $347.1M, led by infrastructure and life sciences growth, while net loss narrowed. DBM Global's backlog and R2's international sales surged, and MediBeacon secured key regulatory approval in China.
INNOVATE Corp. Announces Third Quarter 2025 Results
- Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership - - Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China - - Sp...
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday...
INNOVATE Corp. receives approval to sell Transdermal GFR System in China
INNOVATE announced that MediBeacon, a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVA...
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement...
INNOVATE’s R2 reported Q2 revenue increase of 88% vs last year
INNOVATE announced that R2 Technologies achieved a second-quarter 2025 revenue increase of 88% over the same quarter in 2024. This strong performance underscores R2’s accelerating momentum in the glob...
INNOVATE's Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthrough Glacial...
INNOVATE Earnings Call Transcript: Q2 2025
Q2 2025 saw a 22.7% revenue decline and a net loss of $22 million, driven by lower infrastructure and Spectrum results, partially offset by strong Life Sciences growth. Strategic refinancing extended debt maturities, while DBM Global and R2 maintained robust backlogs and positive outlooks.
INNOVATE Corp. Announces Second Quarter 2025 Results
- Infrastructure: Improved financial flexibility with recent refinancing transactions - - Life Sciences: R2 continuing to see significant year over year growth in system unit sales - - Spectrum: Launc...
INNOVATE Closes Indebtedness Refinancing Transactions
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that it has closed a series of previously announced indebtedness refinancing trans...
INNOVATE Corp. announces early results of exchange offer of senior secured notes
NNOVATE Corp announced the early participation results as of 5:00 p.m., New York City time, on July 30, 2025 of its previously announced exchange offer and consent solicitation to eligible…
INNOVATE Announces Early Results of Exchange Offer of Senior Secured Notes and Solicitation of Consents and Extends Availability of Total Early Exchange Consideration
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced the early participation results as of 5:00 p.m., New York City time, on July 30, 2...
INNOVATE Corp. to Report Second Quarter 2025 Results on August 5th
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the second quarter 2025 on Tuesday,...